12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

MoxDuo IR morphine/oxycodone regulatory update

FDA accepted for review an NDA for MoxDuo IR morphine/oxycodone from QRxPharma to treat moderate to severe acute pain. The PDUFA date is Aug. 26. The company said...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >